The Board of Directors of AB-Biotics calls for an Extraordinary Shareholders Meeting to be held on October 4th at the Barcelona Stock Exchange to approve the proposal to delist all the company’s shares from the Alternative Stock Market (MAB).
In the event that the proposal is approved, Kaneka will leave an opening order, lasting one month from the delisting, for those shareholders who are considering the acquisition of shares. The acquisition price established by Kaneka will be 5 euros per share, in line with the pricing indicated in a report issued by Crowe and a report issued by EY in July evaluating the share price based on various factors and information. This is the same price offered by Kaneka in the voluntary takeover.
AB-Biotics went public in 2010 on the MAB at a price of 2.53 euros per share, and after nine years it will cease trading on the MAB at 5 euros per share.
Kaneka Europe Holding completed the voluntary takeover bid for the 60.24% of the company it did not yet possess the past 23th August. That bid was accepted by shareholders representing 44.11% of that percentage. Kaneka now holds another 26.57% of the capital of the Spanish company, for which it must pay out €16.7 million. Hence Kaneka now controls the group, holding 66.33% of the capital of AB-Biotics.